Prenatal exposure to vanilla or alcohol induces crawling after these odors in the neonate rat: The role of mu and kappa opioid receptor systems

2015 ◽  
Vol 148 ◽  
pp. 58-64 ◽  
Author(s):  
Mirari Gaztañaga ◽  
P. Ezequiel Aranda-Fernández ◽  
M. Gabriela Chotro
Keyword(s):  
Opioid Receptor ◽  
Prenatal Exposure ◽  
Kappa Opioid Receptor ◽  
Kappa Opioid ◽  
Neonate Rat

scholarly journals The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach

2020 ◽  
Author(s):  
Samuel David Clark
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Healthy Volunteers ◽  
Opioid Receptor ◽  
Clinical Data ◽  
Potential Role ◽  
Kappa Opioid Receptor ◽  
Kappa Opioid ◽  
Major Depressive

AbstractThe kappa opioid receptor (KOR) and its endogenous ligands dynorphins (DYN) have been implicated in the development or symptomatology of a variety of neuropsychiatric disorders. This review covers a brief history of the development of KOR agonists and antagonists, their effects in healthy volunteers, and the potential role of DYN/KOR dysfunction in schizophrenia and major depressive disorder from a translational perspective. The potential role of DYN/KOR dysfunction in schizophrenia is based on several lines of evidence. Selective KOR agonists induce affective states in healthy volunteers with similarities to the symptoms of schizophrenia. Studies have shown increased DYN in patients with schizophrenia, although the data have been mixed. Finally, meta-analytic data have shown that opioid antagonists are associated with reductions in the symptoms of schizophrenia. The potential role of DYN/KOR dysfunction in major depressive disorder is also based on a combination of preclinical and clinical data. Selective KOR agonists have shown pro-depressive effects in human volunteers, while selective KOR antagonists have shown robust efficacy in several preclinical models of antidepressant activity. Small studies have shown that nonselective KOR antagonists may have efficacy in treatment-resistant depression. Additionally, recent clinical data have shown that the KOR may be an effective target for treating anhedonia, a finding relevant to both schizophrenia and depression. Finally, recommendations are provided for translating preclinical models for schizophrenia and major depressive disorder into the clinic.

scholarly journals Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus

2015 ◽  
Vol 99 ◽  
pp. 600-609 ◽  
Author(s):  
Jenny Morgenweck ◽  
Kevin J. Frankowski ◽  
Thomas E. Prisinzano ◽  
Jeffrey Aubé ◽  
Laura M. Bohn
Keyword(s):  
Mouse Model ◽  
Opioid Receptor ◽  
Kappa Opioid Receptor ◽  
Kappa Opioid ◽  
Receptor Modulation

scholarly journals Participation of opioid receptors in the cytoprotective effect of chronic normobaric hypoxia

2019 ◽  
pp. 245-253 ◽  
Author(s):  
N.V. Naryzhnaya ◽  
I. Khaliulin ◽  
Y.B. Lishmanov ◽  
M.S. Suleiman ◽  
S.Y. Tsibulnikov ◽  
...  
Keyword(s):  
Cell Death ◽  
Lactate Dehydrogenase ◽  
Opioid Receptor ◽  
Kappa Opioid Receptor ◽  
Normobaric Hypoxia ◽  
Cytoprotective Effect ◽  
Kappa Opioid ◽  
Isolated Cardiomyocytes ◽  
Ldh Release

We studied the role of the delta, micro, and kappa opioid receptor (OR) subtypes in the cardioprotective effect of chronic continuous normobaric hypoxia (CNH) in the model of acuteanoxia-reoxygenation of isolated cardiomyocytes. Adaptation of rats to CNH was performed by their exposure to atmosphere containing 12% of O(2) for 21 days. Anoxia-reoxygenation of cardiomyocytes isolated from normoxiccontrol rats caused the death of 51 % of cells and lactate dehydrogenase (LDH) release. Adaptation of rats to CNH resulted in the anoxia/reoxygenation-induced cardiomyocyte death of only 38 %, and reduced the LDH release by 25 %. Pre-incubation of the cells with either the non-selective OR (opioid receptor) blocker naloxone (300 nM/l), the delta OR antagonist TIPP(psi) (30 nM/l), the selective delta(2) OR antagonist naltriben (1 nM/l) or the micro OR antagonist CTAP (100 nM/l) for 25 minutes before anoxia abolished the reduction of cell death and LDH release afforded by CNH. The antagonist of delta(1) OR BNTX (1 nM/l) or the kappa OR antagonist nor-binaltorphimine (3 nM/l) did not influence the cytoprotective effects of CNH. Taken together, the cytoprotective effect of CNH is associated with the activation of the delta(2) and micro OR localized on cardiomyocytes.

scholarly journals Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior

2019 ◽  
Vol 44 (10) ◽  
pp. 1728-1741 ◽  
Author(s):  
Joshua D. Gross ◽  
Shane W. Kaski ◽  
Karl T. Schmidt ◽  
Elizabeth S. Cogan ◽  
Kristen M. Boyt ◽  
...  
Keyword(s):  
Opioid Receptor ◽  
Differential Regulation ◽  
Kappa Opioid Receptor ◽  
Kappa Opioid ◽  
And Behavior
Sign in / Sign up

Export Citation Format

Share Document